Borlaug, Barry A.

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,669

Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction

Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 1,179

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,009

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap

Shah, S. J., Kitzman, D. W., Borlaug, B. A., van Heerebeek, L., Zile, M. R., Kass, D. A., & Paulus, W. J. (2016) · Circulation

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,003

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 758

Heart Failure With Preserved Ejection Fraction

Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 742

The pathophysiology of heart failure with preserved ejection fraction

Borlaug, B. A. (2014) · Nature Reviews Cardiology

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 726

Impaired Chronotropic and Vasodilator Reserves Limit Exercise Capacity in Patients With Heart Failure and a Preserved Ejection Fraction

Borlaug, B. A., Melenovsky, V., Russell, S. D., Kessler, K., Pacak, K., Becker, L. C., & Kass, D. A. (2006) · Circulation

Cardiovascular and exercise physiologyCardiovascular Function and Risk Factors

Cited by 699

Evaluation and management of heart failure with preserved ejection fraction

Borlaug, B. A. (2020) · Nature Reviews Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 675

Heart Failure With Preserved Ejection Fraction: A Review

Redfield, M. M., & Borlaug, B. A. (2023) · JAMA

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 662

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial

Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., et al. (2021) · Nature Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 618

Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study

Obokata, M., Kane, G. C., Reddy, Y. N. V., Olson, T. P., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 559

Exercise Intolerance in Patients With Heart Failure

Del Buono, M. G., Arena, R., Borlaug, B. A., Carbone, S., Canada, J. M., Kirkman, D. L., Garten, R., Rodriguez-Miguelez, P., Guazzi, M., Lavie, C. J., et al. (2019) · Journal of the American College of Cardiology

Cardiovascular and exercise physiologyHeart Failure Treatment and Management

Cited by 477

Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets

Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 450

Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary

Shah, S. J., Borlaug, B. A., Kitzman, D. W., McCulloch, A. D., Blaxall, B. C., Agarwal, R., Chirinos, J. A., Collins, S., Deo, R. C., Gladwin, M. T., et al. (2020) · Circulation

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 436

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 386

Hemodynamic and Functional Impact of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction

Koepp, K. E., Obokata, M., Reddy, Y. N. V., Olson, T. P., & Borlaug, B. A. (2020) · JACC Heart Failure

Cardiovascular Disease and AdiposityHeart Failure Treatment and Management

Cited by 269

Quality of Life in Heart Failure with Preserved Ejection Fraction: Importance of Obesity, Functional Capacity, and Physical Inactivity

Reddy, Y. N. V., Rikhi, A., Obokata, M., Shah, S. J., Lewis, G. D., AbouEzzedine, O. F., Dunlay, S., McNulty, S., Chakraborty, H., Stevenson, L. W., et al. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiovascular and exercise physiology

Cited by 243

Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction

Borlaug, B. A., Jaber, W. A., Ommen, S. R., Lam, C. S. P., Redfield, M. M., & Nishimura, R. A. (2011) · Heart

Cardiovascular Function and Risk FactorsCardiovascular and exercise physiology

Cited by 229

Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction

AbouEzzeddine, O. F., Davies, D. R., Scott, C. G., Fayyaz, A. U., Askew, J. W., McKie, P. M., Noseworthy, P. A., Johnson, G. B., Dunlay, S. M., Borlaug, B. A., et al. (2021) · JAMA Cardiology

Amyloidosis: Diagnosis, Treatment, OutcomesHeart Failure Treatment and Management

Cited by 220

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Borlaug, B. A., Kitzman, D. W., Davies, M. J., Rasmussen, S., Barros, E., Butler, J., Einfeldt, M. N., Hovingh, G. K., Møller, D. V., Petrie, M. C., et al. (2023) · Nature Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 215

Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality

Verbrugge, F. H., Omote, K., Reddy, Y. N. V., Sorimachi, H., Obokata, M., & Borlaug, B. A. (2022) · European Heart Journal

Heart Failure Treatment and ManagementCardiovascular and exercise physiology

Cited by 214

Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure

Kramer, C. M., Borlaug, B. A., Zile, M. R., Ruff, D., DiMaria, J. M., Menon, V., Ou, Y., Zarante, A. M., Hurt, K. C., Murakami, M., et al. (2025) · Journal of the American College of Cardiology

Cardiovascular Disease and AdiposityHeart Failure Treatment and Management

Cited by 200

Characterization of the Inflammatory-Metabolic Phenotype of Heart Failure with a Preserved Ejection Fraction: A Hypothesis to Explain Influence of Sex on the Evolution and Potential Treatment of the Disease

Packer, M., Lam, C. S. P., Lund, L. H., Maurer, M. S., & Borlaug, B. A. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiovascular Disease and Adiposity

Cited by 185